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have	 been	 noted	 in	 various	 countries.	 In	 addition	 to	 histology,	 molecular	 genetic	
studies	can	help	 in	the	diagnostic	pathway.	Earlier	detection	of	molar	pregnancy	by	
ultrasound	has	 resulted	 in	 changes	 in	 clinical	presentation	and	decreased	morbidity	









reduce	early	deaths	 in	patients	with	extensive	 tumor	burden,	but	 late	mortality	still	
occurs	from	recurrent	resistant	tumors.




Gestational	 trophoblastic	 disease	 (GTD)	 is	 a	 group	 of	 uncommon	
conditions	 associated	with	pregnancy.	Histologically,	 it	 includes	 the	
premalignant	partial	 (PHM)	and	complete	hydatidiform	mole	(CHM),	
as	 well	 as	 the	 malignant	 invasive	 mole,	 choriocarcinoma,	 placental	
site	 trophoblastic	 tumor	 (PSTT),	and	epithelioid	 trophoblastic	 tumor	
(ETT).	The	malignant	forms	can	arise	after	any	type	of	pregnancy	and	
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are	collectively	known	as	gestational	 trophoblastic	neoplasia	 (GTN).	
The	GTD	spectrum	has	recently	been	expanded	to	also	include	atypi-
cal	 placental	 site	 nodule	 (APSN)	 as	 10%–15%	may	 coexist	 with	 or	
develop	 into	 PSTT/ETT.1	 While	 PSTT,	 ETT,	 and	 APSN	 have	 more	
varied	production	of	the	pregnancy	hormone—human	chorionic	gon-
adotropin	(hCG)—all	other	forms	of	GTD	produce	this	hormone	very	
well.	 Indeed,	 hCG	 is	 an	 excellent	 biomarker	 of	 disease	progression,	
response,	 and	 subsequent	 post-	treatment	 surveillance.	 Thus,	 a	 pla-
teaued	or	rising	hCG	level	enables	the	early	detection	of	progression	
of	CHM	and	PHM	to	GTN	 that	occurs	 in	15%–20%,	 and	0.5%–5%	
of	cases,	respectively.2,3	The	use	of	this	biomarker	together	with	the	

















The	 reported	 incidence	 of	 choriocarcinoma	 ranges	 from	 1	 in	
40	000	 pregnancies	 in	 North	 America	 and	 Europe,	 to	 9.2	 and	 3.3	
per	 40	000	 pregnancies	 in	 Southeast	Asia	 and	 Japan,	 respectively.2 
Dietary	deficiency	of	beta-	carotene	and	animal	fat	is	considered	to	be	
etiological	factor	for	complete	mole,	but	not	for	partial	mole.8







blastic	 hyperplasia.	 Histologically,	 complete	 mole	 has	 florid	 cistern	
formation,	 trophoblastic	 proliferation,	 and	 absence	 of	 fetal	 parts.	
Significant	cytological	atypia	and	mitotic	figures	are	common.	 In	the	
first	trimester,	CMH	villi	may	not	be	enlarged	but	have	a	distinct	pol-
ypoid	 appearance	 with	 abnormal	 villous	 stromal	 changes	 and	 mild	
to	 moderate	 trophoblastic	 hyperplasia.	 In	 contrast,	 such	 histologic	




















Histologically,	 choriocarcinoma	 shows	 absence	 of	 chorionic	 villi	
and	presence	of	abnormal	intermediate	trophoblast	and	cytotropho-
blast,	 rimmed	with	 syncytiotrophoblasts	with	 areas	of	 necrosis,	 and	
hemorrhage.	Highly	complex	karyotypes	have	been	reported	and	an	
XX	sex	chromosome	composition	is	seen	in	the	majority.




from	the	mononuclear	 intermediate	 trophoblast	on	 the	maternal	 side	
of	 the	 placental	 bed.	 Tumor	 cells	 have	 irregular	 nuclear	membranes,	








Grossly,	 the	 tumor	appears	 as	white-	tan	 to	brown	discrete	nodules	
or	cystic	hemorrhagic	masses	invading	deep	into	surrounding	tissues.	
Nearly	 half	 arise	 in	 the	 cervix	 or	 lower	 segment	 of	 the	 uterus	 and	
some	in	the	fundus	and	broad	ligament.
Histologically,	 ETT	 arises	 from	 the	 chorionic-	type	 intermediate	
trophoblast.	 Islands	 of	 relatively	 uniform	 intermediate	 trophoblastic	
cells	with	moderate	 amount	 of	 eosinophilic	 to	 clear	 cytoplasm	 and	
round	nuclei	are	surrounded	by	extensive	necrosis	and	associated	with	
a	hyaline-	like	matrix.	The	mitotic	count	ranges	from	0–9	per	10	HPF.	
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Extensive	or	“geographic”	necrosis	is	often	present.	ETT	may	coexist	
with	other	trophoblastic	neoplasms.



















4.3 | Human chorionic gonadotropin monitoring
For	monitoring	of	GTN,	an	hCG	assay	that	can	detect	all	forms	of	hCG	
including	beta-	hCG,	core	hCG,	C-	terminal	hCG,	nicked-	free	beta,	beta	




4.4 | Gestational trophoblastic neoplasia 
after nonmolar pregnancy
As	only	about	50%	of	GTN	follows	molar	pregnancy,	 the	rest	can	
occur	 after	 a	 spontaneous	 abortion,	 ectopic	pregnancy,	 or	 a	 term	
pregnancy.	 Aside	 from	 abnormal	 vaginal	 bleeding,	 other	 clinical	
presentations	 can	 include	 bleeding	 from	metastatic	 sites	 such	 as	


















use	 of	 appropriate	 evacuation	 equipment	 and	 techniques,	 access	
to	blood	products,	careful	intraoperative	monitoring,	and	early	rec-





















•	 When	 there	 is	 a	 rise	 in	 hCG	 for	 three	 consecutive	weekly	









•	 Liver	 metastases	 may	 be	 diagnosed	 by	 ultrasound	 or	 CT	
scanning.
•	 Brain	metastases	may	be	diagnosed	by	MRI	or	CT	scanning.
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Follow-	up	 hCG	 monitoring	 every	 1–2	weeks	 is	 essential	 for	
early	 diagnosis	 of	 and	 management	 of	 postmolar	 GTN.	 On	 the	
other	 hand,	 postmolar	 GTN	 rarely	 occurs	 after	 the	 spontaneous	
return	of	hCG	levels	to	normal,	allowing	for	a	shortened	follow-	up	
period	 for	most	women.	Hence,	 a	 single	 additional	 confirmatory	
normal	hCG	measurement	1	month	after	 first	hCG	normalization	
is	 recommended	 for	 a	 PHM	 and	 monthly	 hCG	 measurements	
should	be	obtained	for	only	6	months	after	hCG	normalization	for	
a	CHM.2,14	Termination	of	pregnancy	 is	 not	 indicated	 if	 acciden-
tal	 pregnancy	occurs	 during	 surveillance	 after	 the	 hCG	 level	 has	
returned	 to	normal.	 In	addition,	data	now	show	that	 it	 is	 safe	 to	
recommend	oral	contraceptives.15
The	risk	of	recurrence	is	low	(0.6%–2%)	after	one	molar	pregnancy,	
although	 much	 increased	 after	 consecutive	 molar	 pregnancies.16 
Mutations	in	NLRP7	and	KHDC3L	have	been	reported	in	women	with	
recurrent	molar	pregnancy.5,6




of	 GTN	 in	 coexisting	 molar	 and	 normal	 pregnancy	 compared	 with	
singleton	molar	pregnancy	is	increased	from	15%	to	20%	to	27%	to	




depends	 on	 stage	 and	 classification.	 In	 the	 2000	FIGO	 staging	 and	
classification	(Tables	1	and	2),	a	risk	score	of	6	and	below	is	classified	
as	low	risk	and	above	6	is	considered	high	risk.









Chemotherapy	 should	 be	 changed	 to	 the	 alternative	 single	 agent	 if	
there	has	been	a	good	response	 to	 the	first	agent	but	 the	hCG	 level	
plateaus	above	normal	during	treatment,	or	if	toxicity	precludes	an	ade-
quate	dose	or	frequency	of	treatment.	If	there	is	an	inadequate	response	











T A B L E  2  WHO	scoring	system	based	on	prognostic	factors.
WHO risk factor scoring with FIGO staging 0 1 2 4
Age <40 >40 — —
Antecedent	pregnancy Mole Abortion Term
Interval	from	index	pregnancy,	months <4 4–6 7–12 >12
Pretreatment	hCG	mIU/mL <103 >103–104 >104–105 >105
Largest	tumor	size	including	uterus,	cm — 3–4 ≥5 —
Site	of	metastases	including	uterus Lung Spleen,	kidney Gastrointestinal	tract Brain,	liver
Number	of	metastases	identified — 1–4 5–8 >8




Box 3 First- line single agent chemotherapy regimens for 






•	 Actinomycin	 D	 pulse	 1.25	mg/m2	 intravenously	 every	
2	weeks.
•	 Actinomycin	D	0.5	mg	intravenously	for	5	days	every	2	weeks
•	 Others:	 MTX	 30–50	mg/m2	 intramuscularly	 weekly,	 MTX	
300 mg/m2	infusion	every	2	weeks
Abbreviations:	MTX-	FA,	methotrexate–folinic	acid.









Higher	WHO	 risk	 score	 (5–6)	 and	 clinicopathologic	 diagnosis	 of	
choriocarcinoma	are	both	associated	with	an	 increased	risk	of	resis-
tance	to	single	agent	chemotherapy.	Lowering	the	threshold	 for	 the	





5.3.2 | High- risk gestational trophoblastic neoplasia










5.3.3 | Ultra high- risk gestational trophoblastic 




first-	line	 multiple	 agent	 chemotherapy.	 Similar	 findings	 have	 been	
reported	by	others.25
For	 those	with	massive	disease,	 starting	with	 standard	chemo-
therapy	may	cause	sudden	tumor	collapse	with	severe	bleeding,	met-
abolic	 acidosis,	 myelosuppression,	 septicemia,	 and	 multiple	 organ	
failure,	 any	or	 all	 of	which	 can	 result	 in	 early	death.	To	avoid	 this,	
the	use	of	 initial	gentle	 rather	 than	 full-	dose	chemotherapy	seems	
logical.	Indeed,	induction	etoposide	100	mg/m2	and	cisplatin	20	mg/
m2	on	days	1	and	2,	repeated	weekly	for	1–3	weeks,	before	starting	
normal	 chemotherapy	 appears	 to	 have	 eliminated	 early	 deaths	 in	
one series26	with	promising	results	now	reported	by	others.25
For	 those	 patients	with	 liver	 metastases,	 with	 or	 without	 brain	









in	 the	EP/EMA	 regimen.	 Some	centers	may	give	whole	brain	 radio-
therapy	3000	cGy	in	200	cGy	daily	fractions	concurrent	with	chemo-
therapy	or	use	stereotactic	or	gamma	knife	radiation	to	treat	existing	
or	 residual	 brain	 metastases	 after	 chemotherapy.27	 Patients	 failing	
EMA-	CO	are	mostly	salvaged	with	paclitaxel	and	etoposide	alternat-
ing	with	 paclitaxel	 and	 cisplatin	 (TE/TP)	 or	with	 EP/EMA.	 In	China,	
the	5FU-	based	FAEV	regimen	is	also	an	effective	salvage	treatment.	
For	women	 failing	 EP/EMA	 or	 TE/TP,	 options	 include	 a	 number	 of	
other	standard	or	high-	dose	chemotherapy	regimens	with	autologous	































•	 High-dose	 chemotherapy	 with	 autologous	 bone	 marrow	 or	
stem	cell	transplant
•	 Immunotherapy	with	pembrolizumab





Surgery	 may	 have	 an	 important	 role	 in	 the	 management	 of	 GTN.	














surgery	also	plays	an	 important	 role	 in	metastatic	disease.	 If	 fer-
tility	preservation	 is	desired,	especially	 in	a	 localized	 lesion,	 con-












6  | ESTABLISHMENT OF A (NATIONAL) 
GTD CENTER
Centralized	care	is	needed	for	optimal	management	of	a	rare	disease	
like	 GTD.	Without	 some	 type	 of	 centralization,	 treatment	 decisions	
will	 be	 inconsistent.	 Centralized	 management	 can	 vary	 from	 only	
hCG	monitoring	 with	 treatment	 advice	 to	 patient	 referral.	 Creating	
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